Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026
Basics
Sector
Healthcare
Industry
Health Information Services
Country
United States
Market cap
2.0B USD
Enterprise value
1.7B USD
Full-time employees
850
Overall health
Drawback:less profitable than most peersless profitable than peers
Drawback:its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback:higher risk than most peers: its share price swings more than most peers’ (beta 1.69 vs a peer median of 0.63)higher risk: bigger price swings (beta 1.69 vs peers 0.63)
About average: growth
Ranks #1,037 of 1,157 healthcare companies (bottom 11%)
Stock-based pay is a large cost. Stock pay was 17% of revenue in 2025.
Schrödinger paid employees $43M in stock in 2025, 17% of its $256M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Schrödinger looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Loss over 12 months, profit last quarter. Lost money in the 12 months to June 2026, but made a $6.0M profit in the quarter to June 2026.
Schrödinger reported a net loss over the last twelve months, but its most recent quarter was profitable ($6.0M). One quarter isn't a trend, but it's closer to profitability than the 12-month figure suggests.
More volatile share price. Beta 1.69: tends to move more than the market.
Schrödinger's shares have swung more with the market than most peers' (beta 1.69, above the market's 1.0).
Sector-normalized EBITDA, earnings, and free cash flow yields.
Earnings yield-2.6%
SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148
EBITDA yield-8.8%
Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401
Free cash flow yield-6.3%
SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000
Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score -0.52Sector median: 0.2215 · MAD: 0.2039
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Schrödinger
Is Schrödinger getting weaker?
Its latest SEC filing (Aug 5, 2026) got stronger: operating margin rose 5.4 points to -59.2%. Its overall score is unchanged at 26/100 since Oct 28, 2026.
How is Schrödinger valued vs its peers?
Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers.Earnings yield -2.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -2.6% vs peers 1.5% (weaker than 100% of peers).
Is Schrödinger growing?
At about the same pace as its peers. Growth scores 56/100 against 1,393 healthcare peers.3-year revenue growth 10.2% vs a peer median of 5.8% (stronger than 62% of peers).3-year revenue growth 10.2% vs peers 5.8% (stronger than 62% of peers).
How profitable is Schrödinger?
Less profitable than most of its peers. Profitability scores 14/100 against 1,393 healthcare peers.Return on invested capital -294.9% vs a peer median of 4.7% (weaker than 100% of peers).Return on invested capital -294.9% vs peers 4.7% (weaker than 100% of peers).
How risky is Schrödinger?
Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Beta 1.69 vs a peer median of 0.63 (weaker than 90% of peers).Beta 1.69 vs peers 0.63 (weaker than 90% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026
Got stronger
Operating margin rose 5.4 points to -59.2%
Worth watching: Schrödinger is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.
Previous quarter
Latest quarter
Change
Revenue (12 months)
254.9M USD
259.0M USD
+1.6%
Net income (12 months)
−103.5M USD
−54.3M USD
−47.5%
Operating margin
-64.7%
-59.2%
+5.4 pts
Free cash flow (12 months)
−148.4M USD
−130.3M USD
−12.2%
Cash
260.3M USD
287.9M USD
+10.6%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Health Information Services companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Gross margin
47.6%
55.8%
64.9%
63.6%
55.7%
▼ 7.9 pts
Operating margin
-80.8%
-81.1%
-81.9%
-100.8%
-65.2%
▲ 36 pts
Net margin
-72.8%
-82.4%
18.8%
-90.2%
-40.4%
▲ 50 pts
Return on assets (ROA)
-13.3%
-21.7%
5.1%
-22.7%
-14.2%
▲ 8.5 pts
Return on equity (ROE)
-18.0%
-33.3%
7.4%
-44.4%
-28.4%
▲ 16 pts
Free cash flow margin
-56.4%
-70.6%
-69.3%
-79.3%
4.9%
▲ 84 pts
Current ratio
6.85×
4.91×
4.25×
3.31×
2.75×
▼ 17%
SDGR price history
Price history is added with the daily price update and will appear after the next one.